{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-078288","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.293713+00:00","generated_at":"2026-05-31T04:52:59.690612+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Citius Pharma obtains partial deferral of milestone payment to Dr. Reddy's under LYMPHIR deal","bullets":["Dr. Reddy's agreed to partial deferral without penalty of a milestone payment due Sep 9, 2024.","Milestone was triggered by FDA approval of LYMPHIR under the 2021 Asset Purchase Agreement.","Payment is by Citius Oncology, Inc.; Citius Pharmaceuticals, Inc. remains guarantor.","All other terms and conditions of the Asset Purchase Agreement remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-078288","json":"https://secwatch.observer/filing/0001213900-24-078288.json","markdown":"https://secwatch.observer/filing/0001213900-24-078288.md","text":"https://secwatch.observer/filing/0001213900-24-078288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024078288/0001213900-24-078288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024078288/ea0214420-8k_citiuspharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:52:59.690612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}